



CLHO Communicable Disease Committee Minutes
August 1, 2025
10:05 a.m. – 11:00 a.m.

Agenda Item	Detail	Action Item(s)		
Welcome and Roll Call Jackson Baures, Co-Chair	Quorum is 50% +1 of committee membership Quorum met.			
Approve minutes Jackson Baures, Co-Chair	Discuss any needed changes for June 6, 2025 minutes No oppositions or abstentions. Minutes approved.	Approved		
CLHO Scheduling Review of Program Elements and Associated Funding Jackson Baures, Co-Chair	CLHO scheduling review of Program Elements and associated funding Summary: Due to potential federal changes in funding, OHA and Program Elements could be affected. At the most recent CLHO meeting a communication process was established: <ul style="list-style-type: none"> OHA will notify the Chairs of the Committee associated with the funding for the affected Program Element; the Chairs will then notify the committee members of the potential funding change and the date and time that CLHO would be meeting to discuss that program. Questions/Discussion <ul style="list-style-type: none"> None. 			
Bicillin® L-A Update Dr. Pete Singson, HIV/STD/TB Medical Director, OHA	Update on the national Bicillin® L-A recall, OHA actions and recommendations Summary of Presentation: Bicillin L-A Recall	Jackson Baures, Co-Chair, will distribute via email the PPT slides and info sheet to meeting attendees		



<p>Jillian Garai, HIV/STI Statewide Nurse Consultant, OHA</p>	<ul style="list-style-type: none"> • Pfizer initiated a voluntary recall 7/10/25 • Affected products were distributed 12/2023-6/2025 • Pfizer completed a Health Hazard Assessment • CDC and Pfizer are not aware of any adverse events • There is no federal guidance concerning notifying patients <p>Clinical Relevance and History</p> <ul style="list-style-type: none"> • Bicillin L-A (BPG) is the primary recommended treatment for syphilis (SY) and congenital syphilis (CY) and is the only treatment for syphilis in pregnancy. • SY and CS are statewide and national epidemics. • Pfizer is the only US manufacturer of BPG. • Due to ongoing shortages, the FDA approved importation of two equivalent products: Extencilline and Lentocilin • OHA maintained a small supply of BPG which was recalled as well as ~30% of the supply sent to LPHAs. <p>Communications Timeline – July 2025</p> <ul style="list-style-type: none"> • Pfizer issued recall • National Coalition of STD (NCSD) and CDC sent emails to state public health agencies • OHA sent recall information to LPHAs and Tribes. • HST sent HAN message to quarantine and return recalled product. • Health Officers notified at HO Caucus Meeting • NCSD members met with Pfizer • CDC sent email with recommendation to reserve Bicillin L-A for pregnant patients • LPHAs were updated at the Congenital Syphilis Case & Data Review meeting. <p>Shortage Summary</p>	<p>If you have questions Contact :</p> <p>Jillian Garai jillian.d.garai@oha.oregon.gov</p> <p>Pete Singson, MD pete.p.singson@oha.oregon.gov</p>		
---	---	--	--	--



	<ul style="list-style-type: none">• Pfizer does not have timeline of next release date, and will give update mid-August• Manufacturing ongoing but no availability timeline• Mid-July Pfizer had at most ~two week supply of inventory• Pfizer providing Bicillin only for confirmed CY and risk of CY patients.• OHA has in stock 10 doses Bicillin and 20 doses Extencilline. <p>Bicillin® L-A Alternatives</p> <ul style="list-style-type: none">• Extencilline and Lentocilin are equivalent medications. They are cleared for importation but are not FDA approved.• The key differences are that they contain soy, do not require refrigeration, and are in powder form.• Availability is unclear. The current expiration date of Extencilline in the U.S. is 10/31/2025. <p>OHA Treatment Recommendations</p> <ul style="list-style-type: none">• Treat non-pregnant patients with Doxycycline.• Consider restarting treatment with a 28-day doxycycline regimen for non-pregnant patients who received 1 or 2 Bicillin doses for late SY.• Use alternative medications for group A strep and rheumatic fever prophylaxis. <p>Questions/Discussion</p> <p>There is concern about giving doxycycline because of the gastrointestinal illness and sensitivity to light associated with it. Are there recommendations for working with that, or giving an exception?</p> <p>Dr. Singson: <i>The Bicillin is for our priority populations, pregnant women and exposed infants. We recommend forewarning patients of the potential side effects of doxycycline, which tend to be mild. For the unhoused population, the exposure to sun is a major consideration and they could</i></p>		
--	---	--	--



	<p><i>refuse treatment. Consideration for Bicillin could be made in that population.</i></p> <p>Jillian Garai: <i>There was a recent shortage in 2023-2024 and we were sending frequent updates on the supply as the shortage improved. We expect the same thing to happen this time. However, we currently have no information about the Bicillin supply, so no timeline for availability. Once we receive Bicillin again regularly, we will open up eligibility and advise everyone. Please use Bicillin for the priority populations. We support it for those who need it most and where it can be most effective in stopping transmission but cannot say yes to all those with barriers and challenges to doxycycline since we do not know when Pfizer will be providing more Bicillin.</i></p> <p>Is there communication on priority actions and a timeline for when we could expect an update, especially if alternative medication availability ends in October which is soon?</p> <p>Dr. Singson: <i>We are expecting a mid-August update from Pfizer, and possibly sooner. We will communicate that as soon as we know.</i></p>			
Announcements	None			
Adjourn	Meeting adjourned 10:29 am.			
Next meeting: Sept. 5, 2025 10:05 am				
Co-Chair: Jackson Baures		Co-Chair: Gerald Dyer		

**Public Health Division of OHA**

HIV, STD & TB (HST): Alison Goldstein, alison.goldstein@odhsosha.oregon.gov

Immunization: Rex Larsen, rex.a.larsen@oha.oregon.gov

Acute & Communicable Disease Prevention (ACDP): Amanda Faulkner, amanda.e.faulkner@oha.oregon.gov

Administrative Support: Jennifer Brown, jennifer.l.brown@oha.oregon.gov

CLHO-CD Membership		Aug 1, 2025
List rev. April 17, 2025		
County/LPHA	Name	Present
Benton	Gerald Dyer	
Benton	Sara Hartstein	
Clackamas	Anna Summer	X
Clackamas	Michelle Mattison	
Clatsop	Jill Quackenbush	X
Clatsop	Mandy Mattison	
Columbia	Lillia Rodgers	
Columbia	Jerry Walker	
Crook	Alanna Spry	X



Deschutes	Rita Bacho	X
Deschutes	Michelle Ashby	
Douglas	Bob Dannenhoffer	
Douglas	Laura Turpen	X
Hood River	Trish Elliott	
Hood River	Lindy McCasland	
Jackson	Bonnie Simpson	X
Jackson	Jackson Baures	X
Josephine	Michael Derossett	
Klamath	Jessica Dale	X
Klamath	Kellie Hansen	
Lane	Katharine Carvelli	X
Lane	Nicole Sticka	
Lincoln	Florence Pourtal	
Lincoln	Shelby Knife	X
Linn	Lynne Rogers	
Linn	Rachel Powell	
Malheur	Rebecca Stricker	X
Malheur	Angie Gerrard	



Marion	Rachel Posnick	X
Marion	Dana Finch	X
Morrow	Sarah Rea	X
Multnomah	Sara McCall	X
Multnomah	Chris Hammel	X
North Central Public Health District (NCPHD)	Marta Fisher	X
Polk	Emily Brateng	X
Tillamook	Austin Close	X
Tillamook	Jaime Craig	
Umatilla	Alisha Lundgren	X
Washington	Callie Gilliam	X
Washington	Kim Repp	
Yamhill	Abigail Gray	X